Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback